Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Plateau technique de référence
Assistance publique – Hôpitaux de Paris (APHP) — équipements et expertise pointus pour les cas complexes
Auteur de référence en rhumatologie
50 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
336.2 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
37
37 articles ont été cités au moins 37fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
6 042
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
142
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
83
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Université Paris Cité · Sorbonne Paris Cité · Assistance Publique – Hôpitaux de Paris
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
HIV persistence in tissues on dolutegravir-based therapy is not associated with resistance mutations to dolutegravir
2026ArticleCommunications Medicine
Comparison of the immunological and virological responses to cART between HIV-1/O and HIV-1/M patients followed up in France
2025ArticleJournal of Antimicrobial Chemotherapy
Safety and immunogenicity of CD40.HIVRI.Env, a dendritic cell-based HIV vaccine, in healthy HIV-uninfected adults: a first-in-human randomized, placebo-controlled, dose-escalation study (ANRS VRI06)
2024ArticleEClinicalMedicine
Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2 × 2 factorial design
2024ArticleThe Lancet Infectious Diseases
Salvage Therapy Including Foscarnet and Ibalizumab for Multidrug-Resistant Human Immunodeficiency Virus Type 2 Infection
2024ArticleClinical Infectious Diseases
High proportion of post-migration HIV acquisition in migrant men who have sex with men receiving HIV care in the Paris region, and associations with social disadvantage and sexual behaviours: results of the ANRS-MIE GANYMEDE study, France, 2021 to 2022
2024ArticleEurosurveillance
Sexual Health of Young Adults Living with Perinatally Acquired HIV in Paris, France: A Qualitative Study
2024ArticleAIDS Patient Care and STDs
Decrease in CD4 T-Cell Count and Risk of Severe Morbid Conditions in People With Human Immunodeficiency Virus Infection With Controlled Viral Load After Initiating Combination Antiretroviral Therapy Between 2006 and 2018
2023ArticleClinical Infectious Diseases
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
GHU APHP CUP SITE HOTEL DIEU
1 PL DU PARVIS DE NOTRE DAME, 75181 PARIS CEDEX 04
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Clinical microbiology reviews · 2016
SUMMARYHIV-1 DNA persists in infected cells despite combined antiretroviral therapy (cART), forming viral reservoirs. Recent trials of strategies targeting latent HIV reservoirs have rekindled hopes of curing HIV infection, and reliable markers are thus needed to evaluate viral reservoirs. Total HIV DNA quantification is simple, standardized, sensitive, and reproducible. Total HIV DNA load influences the course of the infection and is therefore clinically relevant. In particular, it is predictive of progression to AIDS and death, independently of HIV RNA load and the CD4 cell count. Baseline total HIV DNA load is predictive of the response to cART. It declines during cART but remains quantifiable, at a level that reflects both the history of infection (HIV RNA zenith, CD4 cell count nadir) and treatment efficacy (residual viremia, cumulative viremia, immune restoration, immune cell activation). Total HIV DNA load in blood is also predictive of the presence and severity of some HIV-1-associated end-organ disorders. It can be useful to guide individual treatment, notably, therapeutic de-escalation. Although it does not distinguish between replication-competent and -defective latent viruses, the total HIV DNA load in blood, tissues, and cells provides insights into HIV pathogenesis, probably because all viral forms participate in host cell activation and HIV pathogenesis. Total HIV DNA is thus a biomarker of HIV reservoirs, which can be defined as all infected cells and tissues containing all forms of HIV persistence that participate in pathogenesis. This participation may occur through the production of new virions, creating new cycles of infection and disseminating infected cells; maintenance or amplification of reservoirs by homeostatic cell proliferation; and viral transcription and synthesis of viral proteins without new virion production. These proteins can induce immune activation, thus participating in the vicious circle of HIV pathogenesis.
AIDS (London, England) · 2020
We performed an observational prospective monocentric study in patients living with HIV (PLWH) diagnosed with COVID-19. Fifty-four PLWH developed COVID-19 with 14 severe (25.9%) and five critical cases (9.3%), respectively. By multivariate analysis, age, male sex, ethnic origin from sub-Saharan Africa and metabolic disorder were associated with severe or critical forms of COVID-19. Prior CD4+ T cell counts did not differ between groups. No protective effect of a particular antiretroviral class was observed.
AIDS and behavior · 2018
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Communications medicine · 2026 · Journal Article
Mchantaf G, Melard A, Da Silva K, Gardiennet E, et al.
Retrovirology · 2025 · Journal Article
Waast L, Geronimi A, Mélard A, Figueiredo S, et al.
BMC public health · 2025 · Journal Article
Ibrahim N, Bouyer J, Dollfus C, Viard JP, et al.
AIDS (London, England) · 2025 · Journal Article
Merad Y, Mariaggi AA, Karmochkine M, Slama L, et al.
AIDS patient care and STDs · 2024 · Journal Article
Ibrahim N, Viard JP, Ludot-Grégoire M, Lachal J, et al.
The Lancet regional health. Europe · 2024 · Journal Article
Seng R, Frange P, Faye A, Dollfus C, et al.
Journal of virus eradication · 2024 · Journal Article
Ram A, Rascon Velasco V, Mchantaf G, Avettand-Fénoël V, et al.
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024 · Journal Article
Palich R, Arias-Rodríguez A, Duracinsky M, Le Talec JY, et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023 · Journal Article
Choufany M, Weiss L, Makinson A, Roul H, et al.
BMC infectious diseases · 2023 · Journal Article
Slama L, Porcher R, Linard F, Chakvetadze C, et al.
HIV medicine · 2023 · Journal Article
Nikolaichuk M, Mocroft A, Wandeler G, Szlavik J, et al.
HIV medicine · 2022 · Journal Article
Mocroft A, Miro JM, Wandeler G, Llibre JM, et al.
Neuropathology : official journal of the Japanese Society of Neuropathology · 2022 · Case Reports
Bourhis A, Roussel-Robert V, Viard JP, Peyre M, et al.
La Revue du praticien · 2021 · Journal Article
Viard JP
La Revue du praticien · 2021 · Journal Article
Viard JP
La Revue du praticien · 2021 · Journal Article
Viard JP
La Revue du praticien · 2021 · Journal Article
Viard JP
Infectious diseases now · 2021 · Journal Article
Lebeaux D, Jablon E, Flahault C, Lanternier F, et al.
AIDS (London, England) · 2021 · Journal Article
Slama L, Barrett BW, Abraham AG, Palella FJ Jr, et al.
PloS one · 2021 · Journal Article
Kousignian I, Sautereau A, Vigouroux C, Cros A, et al.
PloS one · 2021 · Journal Article
Heid-Picard B, Cochand-Priollet B, Rozenberg F, Giang-Phang D, et al.
Open forum infectious diseases · 2020 · Journal Article
Mocroft A, Lundgren JD, Rockstroh JK, Aho I, et al.
AIDS (London, England) · 2020 · Letter
Etienne N, Karmochkine M, Slama L, Pavie J, et al.
AIDS care · 2020 · Journal Article
Carillon S, Gallardo L, Linard F, Chakvetadze C, et al.
AIDS (London, England) · 2019 · Comparative Study
Fastenackels S, Sauce D, Vigouroux C, Avettand-Fènoël V, et al.
Virologie (Montrouge, France) · 2019 · Journal Article
Hocqueloux L, Viard JP
Presse medicale (Paris, France : 1983) · 2019 · Case Reports
Bourée P, Usubillaga R, Viard JP, Slama L, et al.
EBioMedicine · 2019 · Journal Article
Trémeaux P, Lenfant T, Boufassa F, Essat A, et al.
PloS one · 2018 · Journal Article
Arrive E, Viard JP, Salanave B, Dollfus C, et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018 · Journal Article
Novelli S, Lécuroux C, Avettand-Fenoel V, Seng R, et al.
The Journal of antimicrobial chemotherapy · 2018 · Clinical Trial, Phase III
Pressiat C, Hirt D, Treluyer JM, Zheng Y, et al.
The Journal of antimicrobial chemotherapy · 2017 · Journal Article
Lê MP, Belarbi L, Chaix ML, Dulioust E, et al.
Antimicrobial agents and chemotherapy · 2017 · Journal Article
Valade E, Bouazza N, Lui G, Illamola SM, et al.
The New England journal of medicine · 2017 · Letter
Viard J-P, Gilquin J
Open forum infectious diseases · 2017 · Journal Article
Warszawski J, Avettand-Fenoel V, Rouzioux C, Scott-Algara D, et al.
AIDS research and human retroviruses · 2017 · Journal Article
Scott-Algara D, Warszawski J, Chenadec JL, Didier C, et al.
PloS one · 2016 · Journal Article
Viard JP, Assuied A, Lévy Y, Souberbielle JC, et al.
Geriatrie et psychologie neuropsychiatrie du vieillissement · 2016 · Journal Article
Souberbielle JC, Benhamou CL, Cortet B, Rousière M, et al.
Clinical microbiology reviews · 2016 · Journal Article
Avettand-Fènoël V, Hocqueloux L, Ghosn J, Cheret A, et al.
The Journal of antimicrobial chemotherapy · 2016 · Journal Article
Gantner P, Morand-Joubert L, Sueur C, Raffi F, et al.
PloS one · 2015 · Journal Article
Le Chenadec J, Scott-Algara D, Blanche S, Didier C, et al.
The Lancet regional health. Europe · 2025 · Published Erratum
Ghosn J, Assoumou L, Ouattara M, Rubenstein E, et al.
The Lancet regional health. Europe · 2024 · Journal Article
Ghosn J, Assoumou L, Ouattara M, Rubenstein E, et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024 · Journal Article
Slama L, Barrett BW, Abraham AG, Palella FJ Jr, et al.
International journal of environmental research and public health · 2021 · Journal Article
Faraut B, Tonetti L, Malmartel A, Grabar S, et al.
AIDS and behavior · 2018 · Journal Article
Faraut B, Malmartel A, Ghosn J, Duracinsky M, et al.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2025 · Journal Article
de La Porte des Vaux C, Mariaggi AA, Viard JP
The Journal of antimicrobial chemotherapy · 2021 · Journal Article
Prazuck T, Verdon R, Le Moal G, Ajana F, et al.
Injectable long acting antiretroviral for HIV treatment and prevention: perspectives of potential users
Abstract Background The use of long acting injectable (LAA) antiretroviral drugs may be an alternative option for HIV treatment and prevention. Our study focused on patient perspectives to understand which individuals, a
Strand-specific detection of cell-associated sense and antisense HIV-1 RNAs in splenocytes and PBMC from PLWH
Abstract Background Variation in the level of cell-associated HIV-1 RNA is an important parameter followed in clinical trials focusing on HIV-1 infection, latency or reactivation. In addition to sense products, HIV-1 als
Injectable long acting antiretroviral for HIV treatment and prevention: perspectives of potential users
Abstract Background The use of long acting injectable (LAA) antiretroviral drugs may be an alternative option for HIV treatment and prevention. Our study focused on patient perspectives to understand which individuals, a
Strand-specific detection of cell-associated sense and antisense HIV-1 RNAs in splenocytes and PBMC from PLWH
Abstract Background Variation in the level of cell-associated HIV-1 RNA is an important parameter followed in clinical trials focusing on HIV-1 infection, latency or reactivation. In addition to sense products, HIV-1 als
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
AIDS research and human retroviruses · 2021 · Journal Article
Ghosn J, Abdoul H, Fellahi S, Merlet A, et al.
AIDS research and therapy · 2016 · Journal Article
de Castro N, Braun J, Charreau I, Lafeuillade A, et al.